A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


April 9, 2013

Reformulated Vaginal Microbicide Gel Looks Promising for Rectal Use

A reformulated vaginal microbicide gel has proved safe and well tolerated in HIV-negative women and men using it rectally. Microbicide Trials Network–sponsored researchers at the National Institutes of Health (NIH) tested a reduced glycerin formulation of a tenofovir 1 percent gel and published their findings in the journal PLOS ONE. This study was the first to reformulate the gel by using less glycerin in hopes of creating a product more amenable to rectal use. Beginning in October 2010, the study included 65 men and women at three sites: the University of Pittsburgh, the University of Alabama at Birmingham and Fenway Health in Boston.

The participants were randomly divided into four groups. Three received one of three different products over the period of one week: the reduced glycerin formulation of tenofovir gel, a placebo gel without tenofovir, or a gel that contained the spermicide nonoxynol-9. The fourth group only received the study’s procedures and tests, which included physical and rectal exams, and no gel.

With no significant difference in side effects between groups, 80 percent of the participants reported minor side effects from the gels and 18 percent reported moderate side effects. Ninety-four percent of the participants used the gels daily as directed. Eighty-four percent of the reformulated gel group said they would likely use the gel again, compared with 93 percent of the placebo gel group and 63 percent of those in the nonoxynol-9 group.

The investigators are planning a Phase II trial of the reformulated gel in 186 men who have sex with men and transgender women.

To read the study, click here.

To read a release on the study, click here.

Search: microbicide, rectal, gel, Microbicide Trials Network, tenofovir, PLOS ONE, University of Pittsburgh, University of Alabama at Birmingham, Fenway Health, nonoxynol-9.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (4 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.